| Budget Amount *help |
¥5,193,598 (Direct Cost: ¥3,995,076、Indirect Cost: ¥1,198,522)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,163,598 (Direct Cost: ¥895,076、Indirect Cost: ¥268,522)
Fiscal Year 2010: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
MUC1 is a transmembrane glycoprotein normally expressed on epithelial cells. On many types of cancer cell, MUC1 is overexpressed and aberrantly glycosylated, making MUC1 a potential target for cancer immunotherapy. C3d, the final degradation product of the third complement component (C3), can function as a natural adjuvant. We investigated whether a MUC1-C3d fusion protein could enhance MUC1 immunogenicity and break tolerance to MUC1 in MUC1 transgenic mice. Immunization with MUC1-C3d elicited an IgG response and a strong T cell response. In comparison, only a very weak response was seen in mice immunized with MUC1. Furthermore, in human, the treatment of MUC1-C3d to PBMCs resulted in the induction of higher percentage of CD8+ T cells. Thus, C3d functions as an effective molecular adjuvant when linked to a cancer associated self antigen, and may help break MUC1 tolerance in cancer patients.
|
